Abbott Archives - Page 4 of 34 - Medical Design Sourcing

Here’s what diabetes tech companies are doing on World Diabetes Day

Every November, the diabetes community comes together to recognize both National Diabetes Month in the U.S. and World Diabetes Day.

World Diabetes Day falls on today, Nov. 14, to mark the birthday of Sir Frederick Banting. Banting discovered the insulin hormone along with Charles Herbert Best in 1922.

In an effort to drive awareness and understanding of the chronic condition, a number of medtech companies in the diabetes space undertake efforts each year to celebrate and draw attention to the day and month recognizing the community. We compiled lists in 2021 and 2022 to share some of the initiatives brought forward by these companies.

On World Diabetes Day in 2023, here is what medtech’s diabetes community is doing:

Abbott

Abbott (NYSE:ABT) launched its new “Countdown at a Crossroads” initiative to mark National Diabetes Awareness Month.

The initiative features an animated installation promoting diabetes awareness at the Oculus Center…

Abbott launches dual-chamber pacemaker with first U.S. implants

The Aveir dual-chamber leadless pacemaker [Image courtesy of Abbott]The first U.S. commercial cases have been completed with the Abbott (NYSE: ABT) + Aveir dual-chamber leadless pacemaker technology.

Abbott announced in July that it received FDA approval for the Aveir system. The approval marked the first such nod for a dual-chamber leadless pacing system for treating abnormal or slow heart rhythms.

According to Abbott, more than 80% of people who need a pacemaker require pacing in two chambers of the heart — the right atrium and right ventricle.

The system was included in Time magazine’s recent list of 2023’s best inventions. Matthew Fishler, the lead engineer on the Abbott Aveir project, explained how the company developed the system earlier this year.

Now, the commercially available system has been implanted in patients in the U.S. Dr. Rajesh Banker performed one implant at Hoag Memorial Hospi…

Why Stryker says GLP-1 weight loss drugs could boost joint replacements

Stryker says weight loss drugs could help obese patients slim down for knee and hip replacements. (Pictured is Stryker’s Triathlon Cementless knee.) [Image courtesy of Stryker]

Executives at Stryker, the world’s largest orthopedic device manufacturer, say they’re not afraid that GLP-1 weight loss drugs could hurt demand for joint replacement implants.

Instead, they see GLP-1 drugs — including Ozempic and Wegovy — as a neutral factor or perhaps even a slight positive. That’s because the drugs could help obese and near-obese patients slim down to qualify for knee and hip replacement surgery.

“We don’t anticipate the weight loss drug having a negative impact,” Lisa Kloes, the GM and VP of Stryker’s knee business, said in an interview with Medical Design & Outsourcing. “Actually, we think it’s going to help with implant volumes. There’s qu…

These 11 medical device inventions are the best of 2023, Time magazine says

Time’s best medical device inventions of 2023 include: (clockwise from top left) ViviStim, Coros, Cala kIQ, InVision. [Images courtesy of the companies]

Time magazine recently named 11 medical device inventions among its best inventions of 2023.

The devices highlighted in the ranking ranged from wearables to treat tremor to leadless pacemakers.

Time magazine says it has identified the most impactful ideas, devices and technologies around the world for more than 20 years. The publication says it compiled the list through nominations from its editors and global correspondents, with special attention to certain categories like medical innovations, accessibility, AR/VR, sustainability, wellness and more.

Time then graded each nominee based on a number of key factors that included originality, efficacy, ambition and impact.

This year’s list included 11 devices from startups and major…

Abbott rolls out National Diabetes Awareness Month initiative to promote CGM use

The Countdown at a Crossroads initiative kicks off this month. [Image courtesy of Abbott]Abbott (NYSE:ABT) announced today that it launched its new “Countdown at a Crossroads” initiative for National Diabetes Awareness Month.

The initiative sees Abbott take over the Oculus Center in New York City with an animated installation promoting diabetes awareness. This installation features the faces and stories of people impacted by diabetes, including comedian and talk show host Sherri Shepherd.

Shepherd, a diabetes advocate, uses Abbott’s FreeStyle Libre continuous glucose monitor (CGM) to manage her condition.

“Using a FreeStyle Libre sensor to monitor my glucose levels has helped me get a better grasp on my Type 2 diabetes and ultimately improve my quality of living,” said Shepherd. “Many people living with diabetes aren’t aware of this incredible life-changing technology and Abbott’s efforts to make it accessible…

Abbott teams up with NFL player Damar Hamlin for ‘HeartMates Program’

Damar Hamlin and Dr. Nadim Geloo promote the HeartMates Program. [Image courtesy of Abbott]Abbott (NYSE: ABT) + today announced a new initiative to help those impacted by heart conditions with Buffalo Bills safety Damar Hamlin.

With this announcement, Hamlin becomes the first ambassador for the Abbott HeartMates Program. The program aims to create a community of support for people and caregivers impacted by heart conditions. It enables the sharing of stories and provides emotional support while connecting people with others going through similar journeys.

Hamlin in January collapsed on the field, going into cardiac arrest after making a tackle in an NFL game. He received CPR, automated external defibrillation (AED) and other treatments before being transported to the hospital. Hamlin later confirmed he suffered an episode of commotio cordis. He since made his return to the football field only a few weeks ago.

̶…

Stereotaxis performs first surgical robot procedure with Abbott cardiac mapping tech

Stereotaxis (NYSE:STXS) today announced the first treated patients in the U.S. as part of its surgical robotics collaboration with Abbott (NYSE: ABT) + .

In May, the two companies entered a deal aimed at taking robotic electrophysiology to the next level. It sought to integrate the Abbott EnSite X EP 3D heart mapping system — with Stereotaxis’ robotic magnetic navigation systems. The collaboration combines real-time diagnostic information with the precision and stability of surgical robotics.

Physicians across four U.S. medical centers completed the first integrated procedures in the U.S. They took place at Weill Cornell Medical Center, Mount Sinai Morningside, Banner University Medical Center Phoenix, and Overland Park Regional Medical Center.

Dr. Dhanunjaya Lakkireddy of Overland took part in the initial cases. Lakkireddy said in a news release that the combination of technologies enhanced precision and streaml…

How Abbott developed an accessible, affordable CGM — the FreeStyle Libre system

The FreeStyle Libre 3 reader with the sensor and smartphone. [Image courtesy of Abbott]According to Abbott Diabetes DVP, Technical Operations, Marc Taub, one in nine people in the U.S. live with diabetes.

Speaking at DeviceTalks West in Santa Clara, California, he said that means everyone in the room at the time knows someone with diabetes. The condition requires constant attention and management, something Taub and Abbott aim to alleviate.

“Diabetes is a chronic disease and it’s hard to manage,” Taub said. “It requires a person’s round-the-clock care to manage. At Abbott, it’s our mission to create life-changing technology to help make it easier for people to live better lives.

“In this case, to make it much easier for them to better manage their diabetes.”

Today, Abbott is one of the market leaders in the diabetes space with its continuous glucose monitoring (CGM) technology. It continues updating its…

The biggest cardiovascular stories from TCT 2023

Every year, some of the biggest names in cardiovascular technologies come together in one place for TCT.

This year’s 35th edition of the Transcatheter Cardiovascular Therapeutics annual scientific symposium was no different in San Francisco.

Usual suspects like Medtronic and Abbott released data covering a range of products, while other big names like Edwards, GE HealthCare and more had positive updates on their own technologies.

Last year’s TCT event highlighted some significant trends in the cardiovascular space. Let’s see what this year’s symposium brought.

Abbott’s TriClip, MitraClip shine along with drug-eluting stent

Results from Abbott’s TRILUMINATE pivotal trial reinforced the safety and effectiveness of the TriClip system. Abbott also shared data from the MitraClip EXPAND G4 real-world registry at TCT 2023.

TriClip, a transcatheter edge-to-edge repair (TEER) system, treats patients with symptomat…

What’s next for Abbott’s cardiovascular business?

Abbott (NYSE: ABT) + boosted its vascular device offerings even more with its acquisition of Cardiovascular Systems this year.

Wondering what comes next? Abbott Vascular President Julie Tyler will explain at our DeviceTalks West event, Oct. 18–19 in Santa Clara. (Register here.)

Even as COVID-19 test sales continue to decline and hammer overall revenue, Abbott officials are betting on a productive, innovative pipeline to build momentum — especially in its medical device business. In a keynote interview on the morning of Oct. 18, Tyler will discuss the company’s product platform, innovation process, and what’s to come after the acquisition of Cardiovascular Systems.

How can the merger with Cardiovascular Systems enable Abbott to better help people with vascular diseases?

Find out more at DeviceTalks West.

State of the industry — Execs ‘more bullish than ever’ on medtech

From left: Kevin Lobo, Lisa Earnhardt, Deepak Nath, Bernard Zovighian. All spoke about the state of the industry at The MedTech Conference.

Ernst & Young’s 2023 Pulse of the Industry medical technology report may not have been overly positive, but medtech executives certainly are.

The EY report highlighted sluggish revenues and post-COVID-19 corrections leading to a growth decline. In fact, it was the lowest growth in medtech since 2015. Roughly half of medtech stock price gains realized in 2021 were wiped out by the end of 2022.

However, leading medtech executives, including Stryker CEO Kevin Lobo, only see upwards.

“I feel as bullish as I’ve ever felt in my time in medtech,” Lobo declared.

Lobo, Abbott EVP of Medical Devices Lisa Earnhardt, Smith+Nephew CEO Deepak Nath and Edwards CEO Bernard Zovighian all have positive outlooks for the space. They outlined their views on a panel based around the EY report Monday at T…

Cardinal Health CEO becomes one of medtech’s top-paid executives

Cardinal Health disclosed pay and perks for other leaders and its median employee, as well as severance payouts for two former top executives.

Cardinal Health CEO Jason Hollar [Photo courtesy of Cardinal Health]

Cardinal Health paid CEO Jason Hollar nearly $18.8 million in his first year on the job, the device manufacturer and pharmaceutical distrbutor said in a new executive pay disclosure.

That makes Hollar — who was Cardinal Health’s chief financial officer until his promotion in September 2022 — the second-highest-paid CEO among the world’s largest medical device manufacturers.

Abbott CEO Robert Ford is the top-paid CEO of all medical device manufacturers at $21.7 million in total compensation. Like Cardinal Health, Abbott also has a major pharmaceutical business, but Abbott does not disclose pay for Medical Devices EVP Lisa Earnhardt.

Hollar’s total compensation for fiscal 2…